

company announcement

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 18 May 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.

Under the programme initiated 6 May 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027.

Since the announcement of the programme, the following transactions have been made:

	Number of B shares	Average purchase price	Transaction value, DKK
6 May 2026	199,849	300.66	60,086,659
7 May 2026	200,000	294.37	58,873,625
8 May 2026	210,000	290.45	60,993,987
11 May 2026	210,000	300.49	63,103,075
12 May 2026	210,000	300.81	63,169,735
13 May 2026	210,000	302.39	63,501,546
Accumulated under the programme	1,239,849		369,728,627

The details for each transaction made under the share repurchase programme are published on [novonordisk.com](https://www.novonordisk.com).

Transactions related to Novo Nordisk's incentive programmes have resulted in a net transfer from Novo Nordisk of 204,498 shares in the period from 6 May 2026 to 13 May 2026. The shares in these transactions were not part of the Safe Harbour repurchase programme.

With the transactions stated above, Novo Nordisk owns a total of 33,184,329 B shares of DKK 0.10 as treasury shares, corresponding to 0.7% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 4 February 2026. As of 13 May 2026, Novo Nordisk has since 4 February 2026 repurchased a total 15,999,028 B shares at an average share price of DKK 260.62 per B share equal to a transaction value of DKK 4,169,728,617.

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 67,900 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit [novonordisk.com](https://www.novonordisk.com), [Facebook](#), [Instagram](#), [X](#), [LinkedIn](#) and [YouTube](#).

Contacts for further information

Media:

Ambre James-Brown

+45 3079 9289

globalmedia@novonordisk.com

Liz Skrbkova (US)

+1 609 917 0632

lzsk@novonordisk.com

Investors:

Michael Novod

+45 3075 6050

nvno@novonordisk.com

Jacob Martin Wiborg Rode

+45 3075 5956

jrde@novonordisk.com

Max Ung

+45 3077 6414

mxun@novonordisk.com

Sina Meyer

+45 3079 6656

azey@novonordisk.com

Alex Bruce

+45 34 44 26 13

axeu@novonordisk.com

Christoffer Sho Togo Tullin

+45 3079 1471

cftu@novonordisk.com

Frederik Taylor Pitter

+1 609 613 0568

fptr@novonordisk.com

Mads Berner Bruun

+45 3075 2936

mbbz@novonordisk.com